Olr964 inhibitors represent a class of chemical compounds that interact specifically with the olfactory receptor Olr964, a G-protein coupled receptor involved in the detection of odorants. These inhibitors function by binding to the active site or an allosteric site on the Olr964 receptor, thereby modulating its activity. The structure of Olr964 inhibitors is typically characterized by a diverse array of functional groups that enhance their binding affinity and specificity to the receptor. Common structural motifs include aromatic rings, heterocycles, and various substituents that can interact with amino acid residues within the binding pocket. These structural elements are designed to optimize van der Waals forces, hydrogen bonding, and π-π interactions, ensuring a robust and selective inhibition of the Olr964 receptor.
The synthesis of Olr964 inhibitors often involves multi-step organic synthesis, employing strategies such as palladium-catalyzed coupling reactions, nucleophilic substitutions, and cyclization reactions to construct the core structure. Advanced techniques such as high-throughput screening and computational modeling are utilized to identify potential inhibitors and refine their chemical properties. Once synthesized, these inhibitors are subject to rigorous evaluation through biochemical assays, where their ability to inhibit Olr964 is quantified using metrics like IC50 values. The study of Olr964 inhibitors not only advances the understanding of olfactory receptor functionality but also provides insights into receptor-ligand interactions at a molecular level. Through detailed investigation of these inhibitors, researchers can explore the intricate mechanisms of olfactory signal transduction and receptor dynamics, contributing to the broader field of chemosensory science.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits BCR-ABL tyrosine kinase, potentially impacting signaling pathways associated with Olr964. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor, could modulate signaling pathways that intersect with Olr964's activity. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Inhibits MEK, potentially affecting MAPK/ERK pathway which might be linked to Olr964. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Targets MEK1/2, potentially impacting signaling cascades relevant to Olr964. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
BRAF inhibitor, might influence pathways linked with Olr964. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, likely affecting signaling networks relevant to Olr964. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $130.00 $182.00 | 2 | |
Targets VEGFR, PDGFR, and c-Kit, potentially modulating signaling pathways related to Olr964. | ||||||
Lenvatinib | 417716-92-8 | sc-488530 sc-488530A sc-488530B | 5 mg 25 mg 100 mg | $182.00 $661.00 $1690.00 | 3 | |
Inhibits VEGFR, FGFR, PDGFR, RET, and KIT, likely affecting diverse signaling networks linked to Olr964. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor, could influence pathways that intersect with Olr964's function. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Inhibits MEK, potentially affecting MAPK/ERK pathway which might be relevant to Olr964. | ||||||